Role of MRI and PET CT for radiotherapy planning for head and neck cancer

Conditions

Radiotherapy for head and neck cancer Cancer Head and neck cancer

Bird D, Scarsbrook AF, Sykes J, Ramasamy S, Subesinghe M, Carey B, Wilson DJ, Roberts N, McDermott G, Karakaya E, Bayman E, Sen M, Speight R, Prestwich RJ.

2015-11-0449 citations

10.1186/s12885-015-1867-8

Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study.

Subesinghe M, Scarsbrook AF, Sourbron S, Wilson DJ, McDermott G, Speight R, Roberts N, Carey B, Forrester R, Gopal SV, Sykes JR, Prestwich RJ.

2015-03-1732 citations

10.1186/s12885-015-1154-8

Interventions

1. Patients will have an MRI scan and an 18-fluorodeoxyglucose (18FDG)-PET-CT scan in a radiotherapy mask before the start of radiotherapy treatment 2. A subset of patients within the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age =18 years old 2. WHO performance status 0-2 3. Histologically proven squamous cell carcinoma of the head and neck region 4. Clinical decision made to proceed with a course of radiotherapy of curative intent of 66-70Gy in 33-35 fractions over 6.5–7 weeks with or without concurrent chemotherapy 5. Measurable primary tumour and/or locoregional metastatic lymph nodes on preradiotherapy imaging 6. Able to provide written informed consent 7. Able to lie flat for 1 hour 8. Female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be postmenopausal

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to fluorine-18 FDG 2. Hypersensitivity to iodinated contrast media or gadolinium 3. Poorly controlled diabetes 4. Acute renal failure or moderate renal impairment (estimated glomerular filtration rate < 30 mL/min) 5. Contraindication to MRI imaging, including cardiac pacemaker or presence of MRI incompatible metalwork 6. Claustrophobia precluding MRI imaging 7. Uncontrolled pain 8. Urinary incontinence 9. Female patients must not be pregnant 10. Breastfeeding 11. Serious psychiatric comorbidity

Design outcomes

Primary

Measure	Time frame
Accuracy of imaging with a 18FDG-PET-CT and MRI for identification of head and neck tumours for radiotherapy planning, assessed with intraobserver and interobserver comparison of delineation of tumour target by radiologists and radiation oncologists using PET, MRI and CT imaging; analysis will be done when recruitment is complete	—

Secondary

Measure	Time frame
1. To determine whether CT scan routinely used to plan radiotherapy can be accurately merged with an MRI scan 2. To determine the feasibility of performing MRI and PET-CT imaging during a course of radiotherapy 3. To identify the most useful timepoints for imaging during radiotherapy to track tumour changes 4. To determine whether changes on MRI and PET-CT taken during radiotherapy could be used to improve the radiotherapy plan during treatment These endpoints will be evaluated with quantitative contour comparison tools. Analysis will be done when recruitment is complete.	—

Measure

Time frame

1. To determine whether CT scan routinely used to plan radiotherapy can be accurately merged with an MRI scan 2. To determine the feasibility of performing MRI and PET-CT imaging during a course of radiotherapy 3. To identify the most useful timepoints for imaging during radiotherapy to track tumour changes 4. To determine whether changes on MRI and PET-CT taken during radiotherapy could be used to improve the radiotherapy plan during treatment These endpoints will be evaluated with quantitative contour comparison tools. Analysis will be done when recruitment is complete.

—

Countries

England, United Kingdom

Contacts

Public ContactPam Shuttleworth

Outcome results

None listed